Plaques detected in brain scans forecast cognitive impairment

March 11, 2014

Brain imaging using radioactive dye can detect early evidence of Alzheimer's disease that may predict future cognitive decline among adults with mild or no cognitive impairment, according to a 36-month follow-up study led by Duke Medicine.

The national, multicenter study confirms earlier findings suggesting that identifying silent beta-amyloid plaque build-up in the brain could help guide care and treatment decisions for patients at risk for Alzheimer's. The findings appeared online March 11, 2014, in Molecular Psychiatry, a Nature Publishing Group journal.

"Our research found that healthy adults and those with mild memory loss who have a positive scan for these plaques have a much faster rate of decline on memory, language and reasoning over three years," said lead author P. Murali Doraiswamy, M.D., professor of psychiatry and director of the neurocognitive disorders program at Duke.

Alzheimer's disease – which currently has no cure – afflicts an estimated five million U.S. adults, and is the sixth-leading cause of death among adults, according to the Centers for Disease Control and Prevention. Prior studies have found that changes in the brain begin years, and possibly decades, before cognitive symptoms emerge.

A biomarker that could accurately identify those at greatest risk for cognitive decline could help clinicians better evaluate and treat patients, while also accelerating the testing of drugs to treat the disease.

The current study, which enrolled 152 adults ages 50 and older, was designed to assess whether silent pathological changes in the brain associated with Alzheimer's and detected with positron emission tomography (PET) can predict . Of the participants, 69 had normal cognitive function at the start of the study, 52 had been recently diagnosed with mild , and 31 were diagnosed with Alzheimer's disease.

Subjects completed cognitive tests and underwent PET scans of their brains. This type of imaging uses a radioactive tracer to look for chemical signs of disease in specific tissues.

The radioactive dye used, florbetapir (Amyvid), was approved by the U.S. Food and Drug Administration in 2012 for PET imaging of the brain to estimate beta-amyloid plaque density in patients being evaluated for cognitive impairment. It binds to the beta-amyloid plaques that characterize Alzheimer's disease, helping to measure the extent to which plaques have formed in different brain regions. Using this information, the researchers rated the PET scans as positive or negative.

After 36 months, the researchers repeated the same cognitive exams to reassess participants. They found that those with mild or no cognitive impairment who had evidence of plaques at the trial's start worsened to a greater degree on than those with negative scans.

Thirty-five percent of plaque-positive participants who started with progressed to Alzheimer's, compared to 10 percent without plaque. In addition, plaque-positive participants with mild impairment were more than twice as likely to be started on cognitive-enhancing medication than those without plaque.

Conversely, those with negative scans experienced much less decline: 90 percent of participants with mild cognitive impairment but no plaque did not progress to Alzheimer's. This finding supports the negative predictive value of using PET imaging to identify patients unlikely to decline, which has important implications for both clinical research and treatment.

"Having a negative scan could reassure people that they are not likely to be at risk for progression in the near future," Doraiswamy said.

Doraiswamy cautioned that florbetapir is currently not approved to predict the development of dementia and is not used as a screening tool in cognitively normal people. Future longitudinal studies are needed to further clarify the prognostic role of beta-amyloid plaque PET imaging in a clinical setting.

"Even though our study suggests the test has predictive value in normal adults, we still need additional evidence," Doraiswamy said. "We need longer-term studies to look at the consequences of silent brain plaque build-up, given that it affects 15 to 30 percent of normal older people."

Doraiswamy added that the findings provide support for planned and ongoing multicenter clinical trials of asymptomatic older adults with plaque-positive scans. The research also has implications for other conditions where amyloid might play a role, such as traumatic brain injury (from sports or combat).

Explore further: Alzheimer's plaques in PET brain scans identify future cognitive decline

Related Stories

Alzheimer's plaques in PET brain scans identify future cognitive decline

July 11, 2012
Among patients with mild or no cognitive impairment, brain scans using a new radioactive dye can detect early evidence of Alzheimer's disease that may predict future decline, according to a multi-center study led by researchers ...

FDA approves GE brain imaging tool for Alzheimer's (Update)

October 25, 2013
The U.S. Food and Drug Administration on Friday approved a radioactive imaging chemical from General Electric to help screen patients for Alzheimer's disease and dementia.

New imaging test aids Alzheimer's diagnosis

August 23, 2012
In research studies, scientists regularly use positron emission tomography (PET) scans to detect signs of Alzheimer's disease. Now, Washington University physicians at Barnes-Jewish Hospital are the first in Missouri to offer ...

Researchers identify possible treatment window for memory problems

February 27, 2013
Researchers have identified a possible treatment window of several years for plaques in the brain that are thought to cause memory loss in diseases such as Alzheimer's. The Mayo Clinic study is published in the Feb. 27 online ...

Plaque build-up in your brain may be more harmful than having Alzheimer's gene

October 15, 2012
A new study shows that having a high amount of beta amyloid or "plaques" in the brain associated with Alzheimer's disease may cause steeper memory decline in mentally healthy older people than does having the APOE ɛ4 allele, ...

Amyloid imaging helps in evaluating possible Alzheimer disease

November 27, 2012
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published ...

Recommended for you

Should I stay or should I leave? Untangling what goes on when a relationship is being questioned

August 17, 2017
Knowing whether to stay in or leave a romantic relationship is often an agonizing experience and that ambivalence can have negative consequences for health and well-being.

Kids learn moral lessons more effectively from stories with humans than human-like animals

August 17, 2017
A study by researchers at the Ontario Institute for Studies in Education (OISE) at the University of Toronto found that four to six-year-olds shared more after listening to books with human characters than books with anthropomorphic ...

History of stress increases miscarriage risk, says new review

August 17, 2017
A history of exposure to psychological stress can increase the risk of miscarriage by upto 42 per cent, according to a new review.

Study finds children pay close attention to potentially threatening information, avoid eye contact when anxious

August 17, 2017
We spend a lot of time looking at the eyes of others for social cues – it helps us understand a person's emotions, and make decisions about how to respond to them. We also know that adults avoid eye contact when anxious. ...

Communicating in a foreign language takes emotion out of decision making

August 16, 2017
If you could save the lives of five people by pushing another bystander in front of a train to his death, would you do it? And should it make any difference if that choice is presented in a language you speak, but isn't your ...

Precision medicine opens the door to scientific wellness preventive approaches to suicide

August 15, 2017
Researchers have developed a more precise way of diagnosing suicide risk, by developing blood tests that work in everybody, as well as more personalized blood tests for different subtypes of suicidality that they have newly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.